Metabolic Syndrome is found to be more frequent in chronic obstructive pulmonary disease (COPD) as it seems to be related to systemic inflammation. Chronic Obstructive Pulmonary Disease (COPD) is a growing cause of morbidity and mortality worldwide and will become one of the leading causes of death in near future. This study aims to detect metabolic syndrome in COPD patients and its association with the severity of COPD. The current study was Hospital based cross-sectional observational study. 60 Stable COPD patients were included. Patient of Chronic Obstructive Pulmonary Disease attending general medicine OPD, casualty, admitted to Dr. BRAM Hospital, Raipur (India) medicine ward. After obtaining informed written consent from participants, demographic details, and chief complaints, a Pulmonary Function Test for clinically suspected cases of COPD was obtained. Clinical examinations, including waist circumference, were observed. Blood investigations were done. Staging of COPD was done using GOLD criteria.  The association of the severity of COPD with Metabolic Syndrome was then done using statistical tools. There is no statistically significant difference between the prevalence of Metabolic Syndrome in different COPD stages (P=0.199). There is also a significant difference in pre-FEV1 (P=0.015) and post-FEV1 (P=0.03) values in patients with and without Metabolic Syndrome. At the end of the study, it can be concluded that waist circumference (P=0.007) significantly differs in patients with and without metabolic syndrome. At the same time, other variables like weight, height, BMI, and waist-hip ratio do not show any significant difference.

Reference

1. Mathers CD, Loncar D. Projections of global mortality and disease burden from 2002 to 2030. PLOS Med. 2006 Nov 28;3(11):e442. doi: 10.1371/journal.pmed.0030442, PMID 17132052.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2019 report. Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD2019-v1.7-FINAL-14N.... Accessed January 24, 2019.
3. Ameen NM, El-Deen Mohamed RS, El Mageed NIA, EL Wahab MHA. The metabolic syndrome in patients with chronic obstructive pulmonary disease. Egypt J Chest Dis Tuberc. 2016 Jul 1;65(3):593-6. doi: 10.1016/j.ejcdt.2016.03.008.
4. Widysanto A, Mathew G. Chronic bronchitis. InStatPearls 2021 Jul 17. StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482437/
5. Pahal P, Avula A, Sharma S. Emphysema. Stat. 2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK482217/
6. Zeng G, Sun B, Zhong N. Non-smoking-related chronic obstructive pulmonary disease: a neglected entity? Respirology. 2012 Aug;17(6):908-12. doi: 10.1111/j.1440-1843.2012.02152.x, PMID 22845669.
7. Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J. 2008;31(1):204-12. doi: 10.1183/09031936.00114307, PMID 18166598.
8. Ameen NM, El-Deen Mohamed RS, El Mageed NIA, EL Wahab MHA. The metabolic syndrome in patients with chronic obstructive pulmonary disease. Egypt J Chest Dis Tuberc. 2016 Jul 1;65(3):593-6. doi: 10.1016/j.ejcdt.2016.03.008.
9. Hunt KJ, Resendez RG, Williams K, Haffner SM, Stern MP, San Antonio Heart Study. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart Study. Circulation. 2004;110(10):1251-7. doi: 10.1161/01.CIR.0000140762.04598.F9. PMID 15326061.
10. Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R. Cardiovascular disease in U.S. patients with metabolic syndrome, diabetes and elevated CRP. Diabetes Care. 2005;28(3):690-3. doi: 10.2337/diacare.28.3.690, PMID 15735209.
11. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE et al.. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care. 2005;28(2):385-90. doi: 10.2337/diacare.28.2.385. PMID 15677797.
12. Boyko EJ, de Courten M, Zimmet PZ, Chitson P, Tuomilehto J, Alberti KG. Features of the metabolic syndrome predict higher risk of diabetes and impaired glucose tolerance: a prospective study in Mauritius. Diabetes Care. 2000;23(9):1242-8. doi: 10.2337/diacare.23.9.1242, PMID 10977013.
13. Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM, San Antonio Heart Study. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care. 2003;26(11):3153-9. doi: 10.2337/diacare.26.11.3153. PMID 14578254.
14. Wang JJ, Qiao Q, Miettinen ME, Lappalainen J, Hu G, Tuomilehto J. The metabolic syndrome is defined by factor analysis and incident type 2 diabetes in a Chinese population with high postprandial glucose. Diabetes Care. 2004;27(10):2429-37. doi: 10.2337/diacare.27.10.2429, PMID 15451912.
15. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care. 2005;28(11):2745-9. doi: 10.2337/diacare.28.11.2745, PMID 16249550.
16. Snehalatha C, Baskar ADS, Mary S, Sathish Kumar CK, Selvam S, Catherine S et al.. Temporal changes in prevalence of diabetes and impaired glucose tolerance associated with lifestyle transition occurring in the rural population in India. Diabetologia. 2004;47(5):860-5. doi: 10.1007/s00125-004-1387-6.
17. Akp?nar EE, Akp?nar S, Ertek S, Say?n E, Gülhan M. Systemic inflammation and metabolic syndrome in stable COPD patients. Tuberk Toraks. 2012;60(3):230-7. doi: 10.5578/tt.4018, PMID 23030748.